Last reviewed · How we verify
Febendazole (FENBENDAZOLE)
Febendazole, also known as Fenbendazole, is a small molecule drug in the fenbendazole class that targets Mitogen-activated protein kinase 14. Its mechanism of action and commercial status are not well-documented. It is not FDA-approved for any indications. The safety considerations and pharmacokinetic properties of Febendazole are unknown. Further research is needed to understand its potential therapeutic applications.
At a glance
| Generic name | FENBENDAZOLE |
|---|---|
| Drug class | fenbendazole |
| Target | Mitogen-activated protein kinase 14, Beta-lactamase 1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Safety and Efficacy Study of Different Doses of Oxfendazole Compared to a Single Dose of Albendazole to Treat Trichuris Trichiura Infection in Adults (PHASE2)
- One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole in Chronic Fascioliasis (PHASE2)
- Project Safe Guard-Trauma (NA)
- COVID-19 in Baselland: Validation of Simple and Accurate Tests for COVID-19 Detection, Monitoring and Tracing (ACCURATE-BL-COVID-19)
- Distal vs. Forearm Radial Artery Access (NA)
- Multiple Ascending Dose Study of Oxfendazole in Healthy Adult Volunteers (PHASE1)
- A Study to Investigate Whether the Immediate Use or Deferred Use of an Anti-viral Drug Lamivudine Will Help to Better Safe-guard the Delivery of Chemotherapy in Patients With Cancer Who Are Also Hepatitis B Carriers (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Febendazole CI brief — competitive landscape report
- Febendazole updates RSS · CI watch RSS